SAN ANTONIO BREAST CANCER SYMPOSIUM
(SABCS) December 4-8, 2011, San Antonio, Texas
Everolimus (EVE) restores sensitivity to
aromatase inhibitors (e.g. letrozole has been studied in the neoadjuvant
Temsirolimus restores doxorubicin/cisplatin
sensitivity in head and neck cancer.
EVE restores trastuzumab sensitivity in
Stage IV breast cancer.
What this study showed
Benefit in the present Stage IV BOLER O-2
trial (of EVE potentiating the clinical benefit of exemestane)
confirms the 2009 neoadjuvant impact of EVE restoring sensitivity
of letrozole, and the similar study enhancing the tamoxifen effect.
In addition to restoring sensitivity to
hormonal agents, EVE enhanced the efficacy of chemotherapy (doxorubicin/
cisplatin) and, importantly, of the biologic agent trastuzumab,
in Stage IV breast cancer.
Efforts should be focused on confirming
mammalian target of rapamycin (mTOR) inhibition in the adjuvant
Research needs to be conducted on mTOR
inhibitors with fewer side effects.